A multi-dosing study of AB-423 in HBV patients

Trial Profile

A multi-dosing study of AB-423 in HBV patients

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs AB 423 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2017 According to an Arbutus Biopharma Corporation media release, this trial is expected to be initiated in the first quarter of 2018.
    • 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, this trial is expected to initiate by the end of 2017.
    • 10 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top